IL248255A0 - Methods for treating excess sleep - Google Patents

Methods for treating excess sleep

Info

Publication number
IL248255A0
IL248255A0 IL248255A IL24825516A IL248255A0 IL 248255 A0 IL248255 A0 IL 248255A0 IL 248255 A IL248255 A IL 248255A IL 24825516 A IL24825516 A IL 24825516A IL 248255 A0 IL248255 A0 IL 248255A0
Authority
IL
Israel
Prior art keywords
methods
treating hypersomnia
hypersomnia
treating
Prior art date
Application number
IL248255A
Other languages
English (en)
Hebrew (he)
Original Assignee
Balance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balance Therapeutics Inc filed Critical Balance Therapeutics Inc
Publication of IL248255A0 publication Critical patent/IL248255A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL248255A 2014-04-15 2016-10-09 Methods for treating excess sleep IL248255A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979918P 2014-04-15 2014-04-15
PCT/US2015/025696 WO2015160766A1 (en) 2014-04-15 2015-04-14 Methods for treating hypersomnia

Publications (1)

Publication Number Publication Date
IL248255A0 true IL248255A0 (en) 2016-11-30

Family

ID=54324484

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248255A IL248255A0 (en) 2014-04-15 2016-10-09 Methods for treating excess sleep

Country Status (12)

Country Link
US (3) US10688103B2 (enExample)
EP (1) EP3131904A4 (enExample)
JP (2) JP6672264B2 (enExample)
KR (1) KR20170005415A (enExample)
CN (1) CN106459066B (enExample)
AU (2) AU2015247829B2 (enExample)
CA (1) CA2945705A1 (enExample)
EA (1) EA201692061A1 (enExample)
IL (1) IL248255A0 (enExample)
MX (1) MX2016013340A (enExample)
WO (1) WO2015160766A1 (enExample)
ZA (1) ZA201607068B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
US11529358B2 (en) 2017-05-10 2022-12-20 Emory University Treatment of conditions associated with myotonic dystrophy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006137746A (ja) * 2004-10-13 2006-06-01 Otsuka Pharmaceut Factory Inc オレキシン誘導組成物
US8729067B2 (en) 2006-05-22 2014-05-20 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
WO2008085888A1 (en) 2007-01-05 2008-07-17 Arena Pharmaceuticals, Inc. G protein-coupled receptor and modulators thereof for the treatment of gaba-related neurological disorders including sleep-related disorders
EP2300015A4 (en) * 2008-03-12 2011-06-29 Univ Emory USE OF GABAA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLIP AND DISEASES RELATED TO EXCESSIVE SLIP
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US8946206B2 (en) * 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
JP2014511382A (ja) 2011-02-23 2014-05-15 コエルルウス リミテッド フルマゼニル錯体、それを含む組成物、およびその使用
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol

Also Published As

Publication number Publication date
JP2020105200A (ja) 2020-07-09
AU2019268190A1 (en) 2019-12-12
US20200360398A1 (en) 2020-11-19
JP6672264B2 (ja) 2020-03-25
EA201692061A1 (ru) 2017-03-31
JP2017511386A (ja) 2017-04-20
CN106459066B (zh) 2020-07-07
EP3131904A1 (en) 2017-02-22
EP3131904A4 (en) 2017-11-22
AU2015247829A1 (en) 2016-10-27
AU2015247829B2 (en) 2019-12-05
US10688103B2 (en) 2020-06-23
US20180169107A1 (en) 2018-06-21
MX2016013340A (es) 2017-02-09
CA2945705A1 (en) 2015-10-22
US20230115839A1 (en) 2023-04-13
KR20170005415A (ko) 2017-01-13
ZA201607068B (en) 2023-01-25
CN106459066A (zh) 2017-02-22
WO2015160766A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
IL304252A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
IL249600A0 (en) Bone marrow cell transplant treatment
PT3492632T (pt) Métodos para o tratamento de materiais que contêm lítio
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
GB201405800D0 (en) Process
GB201405210D0 (en) Process
SG11201609350XA (en) Methods for inhibiting necroptosis
GB201406890D0 (en) Process
GB201401430D0 (en) Treatment process
GB201404468D0 (en) Process
IL249936A0 (en) Methods for treating hypotension
IL249475A0 (en) Methods for treating itching
GB201402950D0 (en) Process
SG11201605070UA (en) Novel methods for treating cancer
GB201402782D0 (en) Process
GB201400137D0 (en) Process
SG11201609522TA (en) Methods for treating cardiovascular diseases
GB201414192D0 (en) Apparatus for treating animals
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
PT3172297T (pt) Método para tratar algas
GB201405209D0 (en) Process
GB201403057D0 (en) Process
ZA201607068B (en) Methods for treating hypersomnia